Open an account

Amphastar Pharmaceuticals

AMPH · NASDAQ

$25.94−$0.20 (−0.77%)TodayMarket closed ·
Prev close $26.14

About AMPH

Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient. The company is headquartered in Rancho Cucamonga, California and currently employs 1,976 full-time employees. The company went IPO on 2014-06-25. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The firm manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The firm manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.

Employees
1,976
Headquarters
Rancho Cucamonga, California
Listed
Jun 25, 2014
Sector
Health Care
Industry
Pharmaceuticals
Website
amphastar.com

AMPH key statistics

Market cap
1.11B
Price-earnings ratio
15.47
Dividend yield
—
Average volume
462.05K
Volume
361.35K
Open price
$26.24
High today
$26.61
Low today
$25.82
52 Week high
$29.52
52 Week low
$16.65

Amphastar Pharmaceuticals (AMPH) at a glance

As of Oct 20, 2026, Amphastar Pharmaceuticals (AMPH) shares are priced at $25.94, giving the company a market cap of 1.11B and a price-to-earnings ratio of 15.47.

Today the stock has traded between $25.82 and $26.61. The current price is 0.5% above the day's low and 2.5% below its high.

Volume so far is 361.35K shares, below the average of 462.05K shares a day.

Over the past year Amphastar Pharmaceuticals has ranged from $16.65 to $29.52, and now sits 72% of the way up that range.

Amphastar Pharmaceuticals met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported $0.91 per share against an estimate of $0.6325.

The average analyst price target is $22.95, 11.5% below the current price, from 6 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

0%of 6 analyst ratings say Buy
  • Buy0.0%
  • Hold83.3%
  • Sell16.7%
Price target · 8 analystsAvg $22.95
Low
$20.20
Now
$25.94
High
$31.50

AMPH earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 18.1% on average.

  1. Q3 FY24: reported $0.96 per share against an estimate of $1.01
  2. Q4 FY24: reported $0.92 per share against an estimate of $0.9639
  3. Q1 FY25: reported $0.74 per share against an estimate of $0.7004
  4. Q2 FY25: reported $0.85 per share against an estimate of $0.7558
  5. Q3 FY25: reported $0.93 per share against an estimate of $0.841
  6. Q4 FY25: reported $0.73 per share against an estimate of $0.9407
  7. Q1 FY26: reported $0.42 per share against an estimate of $0.7191
  8. Q2 FY26: reported $0.91 per share against an estimate of $0.6325

AMPH news

  • Press releasePRNewswire

    Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference

  • Press releasePRNewswire

    Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026

  • Press releasePRNewswire

    Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6, 2026

  • Stjepan Kalinic

    Two Years to Build or Pay 200% — Which US Pharma Stocks Win?

  • Avi Kapoor

    Crude Oil Gains 2%; Comcast Shares Spike Higher

  • 12 Health Care Stocks Moving In Friday's Intraday Session

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

Similar companies

Companies in the same industry as Amphastar Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.